|Bid||0.00 x 1000|
|Ask||0.00 x 1300|
|Day's Range||49.99 - 50.35|
|52 Week Range||35.30 - 51.55|
|Beta (5Y Monthly)||0.20|
|PE Ratio (TTM)||62.99|
|Forward Dividend & Yield||1.40 (2.78%)|
|Ex-Dividend Date||Aug 06, 2019|
|1y Target Est||53.05|
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.
Shares of Genprex Inc. climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track designation. Genprex is testing the therapy in combination with AstraZeneca's Tagrisso for certain non-small cell lung cancer patients. AstraZeneca said in October that Tagrisso brought in $2.3 billion in sales year-to-date, an 82% jump compared to the year prior. Its stock was up 0.7% on Wednesday. Genprex plans to start a Phase I/II clinical trial for the investigational combination treatment. Genprex's stock is up 12% over the past year, while the S&P 500 has gained 24%.
BEIJING/ZURICH Jan 22 (Reuters) - Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another win for the Swiss drugmaker in its second-biggest market where rising demand has helped drive its increased sales and profit. Kadcyla, which also recently won expanded approval in the United States, Canada and Europe for more breast-cancer patients, is an antibody-drug conjugate (ADC), a class of therapies that combine monoclonal antibodies with cytotoxic chemical that in 2019 picked up momentum with a record number of U.S. approvals.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis® CDx test as a companion diagnostic to AstraZeneca’s (LSE/OMX Nordic/NYSE: AZN) and Merck’s PARP inhibitor Lynparza® (olaparib) for men with metastatic castration-resistant prostate cancer.
AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver cancer.
BT , Danone, Microsoft and Sony are among 178 companies with top marks in the latest global ranking of transparency and action on climate change. Japan and the U.S. were the countries with the headquarters of the most 'A List' companies individually, while regionally, Europe as a bloc was home to the highest number. Companies are coming under pressure from customers and investors to step up efforts to help slow climate change in accordance with the 2015 Paris climate agreement to phase out greenhouse gas emissions by shifting away from fossil fuels.
U.S. bank JPMorgan Chase & Co said it plans to buy a building in central Paris to house up to 450 staff in coming years, as it relocates some services from London after Britain's exit from the European Union. The expansion is expected to make the French capital where it currently has 260 staff, its second-largest base in Europe behind London, which has 10,000 staff, JPMorgan said.
Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday. Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program.
Acasti Pharma (NASDAQ:ACST) is a classic example of the extreme volatility of small-cap biotech stocks. It was only in late December that the shares were fetching $2.87, up from $1 a year earlier. But now ACST stock is trading around 79 cents, with a market cap of about $70 million. To provide some context, in 2013 the shares were trading around $40.Source: Shutterstock Founded in 2002, Acasti specializes in developing prescription drugs that use omega-3 fatty acids derived from krill oil. Keep in mind that those acids have been shown to effectively reduce triglycerides, thereby helping to make people's hearts healthier.The problem is that the underlying science is extremely complex and challenging. That was certainly highlighted recently when Acasti received disappointing results from a Phase 3 clinical trial of its CaPre drug. The drug was supposed to treat patients who suffer from severe hypertriglyceridemia, in which triglyceride blood levels range from 500 mg/dL to 1500 mg/dL.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs for the trial, it did have some positive outcomes. For example, the drug produced a 30.5% median reduction in triglyceride levels over a 12-week term. The median triglyceride reduction of patients taking the drug in combination with a statin was 42.2%, versus a 31.5% median reduction for those taking a placebo and a statin.So what went wrong? According to Acasti's press release: "Both the placebo and CaPre study groups experienced significant reductions in triglycerides within the first four weeks from baseline, and even though the difference at 12 and 26 weeks was in favor of CaPre, due to the unexpectedly large placebo response, TRILOGY 1 did not reach statistical significance." * The Top 5 Dow Jones Stocks to Buy for 2020 Despite this setback, Acasti is not giving up. The company is analyzing the data to determine the reasons for the endpoint miss. The remaining top-line data from the trial will be released in the next couple of weeks, and the FDA is expected to issue more analysis about the secondary endpoints of the trial within the next couple months. Additional positive data could emerge, boosting ACST stock.But I think investors should be extremely cautious about ACST. Just look at AstraZeneca (NYSE:AZN), whose fish-derived heart drug Epanova also failed to meet its primary endpoint in a clinical trial. In fact, the company decided to stop developing the drug, resulting in a $100 million writeoff. The Bottom Line on ACST StockACST is all about CaPre. So if the drug is not progressing sufficiently, the company's prospects will certainly be ominous.It's also important to point out that Acasti's rival, Amarin (NASDAQ:AMRN), is continuing to make headway with its fish-oil drug, Vascepa. During the latest reported quarter, Vascepa's sales soared 103% year-over-year to $112.4 million. That will definitely make things tougher on ACST.Also, consider that Amarin recently received FDA approval for an expanded indication for Vascepa. The drug was shown to be effective for patients who have elevated triglyceride levels of ≥150 mg/dL. According to Dr. Deepak Bhatt, an executive director of the Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, the treatment "represents one of the most important developments in the prevention and treatment of cardiovascular disease since statins…"Vascepa's annual sales could reach $4 billion within the next three or four years. In other words, for investors looking for a play on the cardiovascular market, Amarin looks like a pretty good option, while ACST stock looks like a name that they should avoid.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 5 Dow Jones Stocks to Buy for 2020 * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure * 3 Tech Stocks to Play Ahead of Earnings The post Does Acasti Stock Have a Future? appeared first on InvestorPlace.
Amarin (NASDAQ:AMRN) stock has been choppy for the past year, as the price has made multiple attempts to move above the $23-$24 range. However, this has been a stubborn line of resistance, considering the stock price is currently around $20.Source: Pavel Kapysh / Shutterstock.com Despite this, Amarin stock has still been a pretty good bet over the years. After all, the five-year average return is close to 80%.So, what now? Could there be an opportunity with Amarin stock? Well, I think so.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo see why, let's get a brief backgrounder on the company. Founded in 1993, Amarin is one of the leaders in leveraging lipid science and polyunsaturated fatty acids to create pharmaceuticals to improve heart health. The main drug is Vascepa, which has posted robust growth. In the latest quarter, revenues hit $112.4 million, up 103% on a year-over-year basis. This has been due to substantial increases in the number of subscribers and higher levels of prescriptions per prescriber. * 10 Cheap Stocks to Buy Under $10 However, the key for Amarin is that it recently gained FDA approval for wider applications for Vascepa. This decision, ironically enough, came on Friday the 13th last month -- but of course, this really should be a very lucky day. Vascepa's DevelopmentThe new indication and label expansion -- which is the result of a decade of research and development -- is for a therapy to reduce "the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease."Yes, this is kind of medical jargon. But when boiling things down, the new use for Vascepa is a game changer.According to Dr. Deepak Bhatt, an executive director of the Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, the treatment "represents one of the most important developments in the prevention and treatment of cardiovascular disease since statins…"The market opportunity is enormous, as there -- on average -- one cardiovascular death occurring every 40 seconds in the U.S. Also, the financial costs of cardiovascular disease events are burdensome at about $500 billion a year -- the most costly in the U.S. The CompetitionThere are a myriad of companies trying to do what Amarin has done; that is, using lipid therapies for cardiovascular disease. But, the science has proven quite complex and challenging.Note that there have been some recent examples of Phase 3 trials that shown disappointing results, such as from AstraZeneca (NYSE:AZN) and Acasti Pharma (NASDAQ:ACST). In fact, since December, ACST has plunged from $2.87 to around $0.80 per share.In fact, Cantor Fitzgerald analyst Louise Chen recently wrote after these companies' failures that "AMRN has been the only company in its class with an outcomes study (REDUCE-IT) that has shown a statistically significant benefit in reducing [cardiovascular] disease. We think the news today underscores our view that AMRN is an interesting asset in a consolidating space." Bottom Line On Amarin StockLast week, Amarin issued revised guidance for 2019. Revenues are now expected to range from $410 million to $425 million, which is at or slightly above the upper end of the prior forecast. The company also noted that beyond 2020, Vascepa's total net revenue "will grow to reach multiple billions of dollars" because "the history of other therapies for chronic conditions suggests that growth builds over multiple years."Given this, the growth story should be robust for quite some time. This should also stir up mergers & acquisitions interest from the mega pharma companies like Pfizer (NYSE:PFE), Merck (NYSE:MRK) and even AZN.Let's face it, they need to fill their pipelines with blockbuster drugs -- and these companies certainly have the resources to pay a premium price for Amarin.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Stocks to Buy Under $10 * 5 Retail Stocks Placer.ai Thinks Can Win Big in 2020 * 6 Cheap Stocks to Buy Under $7 The post Why Amarin Stock Is Poised for a Healthy 2020 appeared first on InvestorPlace.
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Under the deal, inked in November 2018, NextCure gave Eli Lilly access to its proprietary platform for research aimed at developing and commercializing new cancer therapies.
The seller converted the office space — leased heavily by local biotech companies — to lab suites, then sold the buildings just three years after buying them.
AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
Amarin stock popped Monday after rivals AstraZeneca and Acasti Pharma reported disappointing outcomes for their Vascepa-rivaling high triglycerides treatments.
Shares of Amarin Corp. PLC rose 4.8% in active afternoon trading Monday, after makers of drugs that rival Amarin's Vascepa, which is used to lower the risk of cardiovascular events in patients with high triglyceride levels reported disappointing trial results. Trading volume in Amarin's stock was 13.6 million shares, well above the full-day average of about 9.9 million shares. Acasti Pharma Inc. said a phase 3 trial of CaPre failed to meets its primary endpoint, of reducing triglycerides by 20% compared with placebo. The median triglyceride reduction in patients taking CaPre was 30.5% while the median reduction of patients taking a placebo was 27.5%. Acasti's stock plummeted 64% on volume of 48 million shares. And AstraZeneca PLC shares fell 0.6% said it would discontinue the phase 3 trial of Epanova given its "low likelihood of demonstrating a benefit" to patients at increased risk of cardiovascular events, and that it would take a charge of up to $100 million as a result. Amarin's stock has run up 30.5% over the past three months, while the S&P 500 has gained 10.5%.
AstraZeneca and Acasti Pharma each disclosed disappointing results from cardiovascular drugs derived from fish or krill oil.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
AstraZeneca will take a $100m writedown after trials of a heart disease drug showed it to be ineffective in treating a particular cardiovascular condition. After the disappointing results, the pharmaceutical group said it would discontinue trials on the drug, known as Epanova, and carry out a review into its $533m value on the company’s balance sheet. Epanova is used in the US to treat a condition involving high levels of triglycerides in the bloodstream that can be a forerunner of heart disease.
(Bloomberg) -- Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.AstraZeneca Plc will stop testing a fish-oil pill for a form of harmful cholesterol that was in the most advanced and expensive stage of clinical trials.The medicine, called Epanova, didn’t stand a very high likelihood of showing a benefit when combined with a statin for patients at risk of heart disease due to high levels of LDL (or bad) cholesterol, Astra said in a statement Monday.Epanova, gained in Astra’s 2013 takeover of Omthera Pharmaceuticals, is a prescription omega-3 capsule approved to treat high levels of triglycerides, which also clog up patients’ arteries. Fish oils contain fatty acids that help combat deposits in blood vessels.“Epanova would have rounded out Astra’s growing suite of differentiated cardiovascular disease assets,” Andrew Baum, an analyst at Citi, wrote in a note to clients. He cited medicines such as Brilinta for heart disease, Farxiga, a diabetes drug that’s also approved for heart failure, and roxadustat, an anemia treatment.A write-down of as much as $100 million related to inventories will impact core earnings in the fourth quarter of 2019, Astra said. The company will review the drug’s $533 million value as an intangible asset. Astra shares were little changed in London.The failure is “a disappointment,” but isn’t having much impact on the stock because the drug’s estimated contribution to future sales was modest, according to Citi’s Baum. Analysts surveyed by Bloomberg expected the medicine to generate peak revenue of $145 million in 2023.(Updates with analyst’s comment in fourth paragraph)To contact the reporters on this story: Marthe Fourcade in Paris at firstname.lastname@example.org;Erin Roman in London at email@example.comTo contact the editors responsible for this story: Eric Pfanner at firstname.lastname@example.org, John LauermanFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.